AstraZeneca的病原体在第三阶段试验中显著降低了抗治疗的高血压病人的血压。 AstraZeneca's baxdrostat significantly lowered blood pressure in treatment-resistant hypertension patients in a phase 3 trial.

AstraZeneca's Baxdrostat是抗治疗高血压的一种新药物,在第三阶段试验中达到其主要终点,与12周后的安慰剂相比,显著降低了24小时的收缩性血压。 AstraZeneca's baxdrostat, a new drug for treatment-resistant hypertension, met its primary endpoint in a phase 3 trial, significantly lowering 24-hour systolic blood pressure compared to placebo after 12 weeks. 该药物抑制了aldosterone,表现出日夜持续的影响,针对心血管事件的关键风险期。 The drug, which inhibits aldosterone, showed sustained effects throughout the day and night, targeting a key risk period for cardiovascular events. 计划在年终前提交成果支持监管报告,并正在进一步研究初级肾病、慢性肾病和心脏衰竭预防。 Results support regulatory submissions planned before year-end, with further studies underway for primary aldosteronism, chronic kidney disease, and heart failure prevention.